The Efficacy of Hypertonic Lactate Solution in CABG(Coronary Artery Bypass Grafting) Patients
Primary Purpose
Low Cardiac Output
Status
Completed
Phase
Phase 3
Locations
Indonesia
Study Type
Interventional
Intervention
Hypertonic lactate
Ringer's lactate
Sponsored by
About this trial
This is an interventional treatment trial for Low Cardiac Output focused on measuring coronary, artery, bypass, grafting, IV, cardiac output
Eligibility Criteria
Inclusion Criteria:
- Male or female
- 45 to 80 years
- CABG patients with on or off pump procedure
- Ejection fraction < 50%
- Given informed consent
Exclusion Criteria:
- Combined operations
- Severe arrhythmia(VT, AF rapid response, heart blocks) and severe hemodynamic imbalance
- Severe bleeding and/or re-operation
- Hypernatremia > 155 mMol/L
- Severe liver failure(SGOT, SGPT 2x normal)
- Severe renal failure(Creatinine > 2 mg. %)
- Major diseases(eg. cancer)
Sites / Locations
- National Cardiac Center, Department of Surgery and Intensive Care Unit, Harapan Kita Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Group 1
Group 2
Arm Description
Hypertonic lactate
Ringer's lactate
Outcomes
Primary Outcome Measures
Hemodynamic status
Secondary Outcome Measures
Safety of hypertonic sodium lactate for maintaining hemodynamic stability
Full Information
NCT ID
NCT00529711
First Posted
September 12, 2007
Last Updated
September 12, 2007
Sponsor
Innogene Kalbiotech Pte. Ltd
1. Study Identification
Unique Protocol Identification Number
NCT00529711
Brief Title
The Efficacy of Hypertonic Lactate Solution in CABG(Coronary Artery Bypass Grafting) Patients
Official Title
The Efficacy of Hypertonic Lactate Solution in CABG(Coronary Artery Bypass Grafting) Patients
Study Type
Interventional
2. Study Status
Record Verification Date
September 2007
Overall Recruitment Status
Completed
Study Start Date
July 2005 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
July 2006 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Innogene Kalbiotech Pte. Ltd
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Previous clinical trials with 11.2% Hypertonic Ringer's Lactate in post-operative CABG subjects have shown an increase in several cardiac performance parameters, with lesser volume of resuscitation fluid required to reach circulation volume, as compared to Sodium Chloride.It also does not cause hyperchloremic acidosis, which is of value in treating shock patients.
The primary objectives of this prospective, randomized, open-label trial are to evaluate the clinical efficacy of hypertonic lactate in comparison to Ringer's lactate to maintain hemodynamic stability in intra- and post-CABG subjects in relation to hemodynamic status and body fluid balance, as well as to assess its safety in terms of lab parameters and occurrence of adverse events.The secondary objectives are to evaluate comparative clinical efficacy of the two fluids in relation to reduction in concomitant drug utilization, duration of ventilator usage, length of stay in ICU as well as total duration of hospitalization and neurocognitive status upto a period of 1 year post-CABG.
Detailed Description
Details provided in summary.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Low Cardiac Output
Keywords
coronary, artery, bypass, grafting, IV, cardiac output
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
66 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Group 1
Arm Type
Experimental
Arm Description
Hypertonic lactate
Arm Title
Group 2
Arm Type
Active Comparator
Arm Description
Ringer's lactate
Intervention Type
Drug
Intervention Name(s)
Hypertonic lactate
Other Intervention Name(s)
Totilac
Intervention Description
Solution given parenterally as follows:
Intraoperative 3 ml./kg BW for 15 minutes at beginning of surgery; During surgery 1.5 ml/kg BW/hour; Second loading 1.5 ml/kg BW for 15 minutes after protamin administration; Post-operative 1 ml/kg BW/hour for 12 hours.
Intervention Type
Drug
Intervention Name(s)
Ringer's lactate
Intervention Description
Solution given parenterally as follows:
Intraoperative 3 ml./kg BW for 15 minutes at beginning of surgery; During surgery 1.5 ml/kg BW/hour; Second loading 1.5 ml/kg BW for 15 minutes after protamin administration; Post-operative 1 ml/kg BW/hour for 12 hours.
Primary Outcome Measure Information:
Title
Hemodynamic status
Time Frame
During and 12 hours after CABG surgery
Secondary Outcome Measure Information:
Title
Safety of hypertonic sodium lactate for maintaining hemodynamic stability
Time Frame
During and 12 hours after CABG surgery
10. Eligibility
Sex
All
Minimum Age & Unit of Time
45 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Male or female
45 to 80 years
CABG patients with on or off pump procedure
Ejection fraction < 50%
Given informed consent
Exclusion Criteria:
Combined operations
Severe arrhythmia(VT, AF rapid response, heart blocks) and severe hemodynamic imbalance
Severe bleeding and/or re-operation
Hypernatremia > 155 mMol/L
Severe liver failure(SGOT, SGPT 2x normal)
Severe renal failure(Creatinine > 2 mg. %)
Major diseases(eg. cancer)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Xavier Leverve, MD, PhD
Organizational Affiliation
Director, INSERM-E0221-Bioenergetique Fondamentale et appliquee, Universite Joseph Fourier, France
Official's Role
Principal Investigator
Facility Information:
Facility Name
National Cardiac Center, Department of Surgery and Intensive Care Unit, Harapan Kita Hospital
City
Jakarta
ZIP/Postal Code
114210
Country
Indonesia
12. IPD Sharing Statement
Learn more about this trial
The Efficacy of Hypertonic Lactate Solution in CABG(Coronary Artery Bypass Grafting) Patients
We'll reach out to this number within 24 hrs